Clinical trials of human papillomavirus vaccines and beyond.
about
Anal cancer and intraepithelial neoplasia screening: A reviewHealth Disparities in the Immunoprevention of Human Papillomavirus Infection and Associated MalignanciesEpidemiology of Human Papillomavirus-Positive Head and Neck Squamous Cell CarcinomaEurogin 2016 Roadmap: how HPV knowledge is changing screening practice.HPVdb: a data mining system for knowledge discovery in human papillomavirus with applications in T cell immunology and vaccinology.Safety of human papillomavirus vaccines in healthy young women: a meta-analysis of 24 controlled studiesImpact of smoking on the quantity and quality of antibodies induced by human papillomavirus type 16 and 18 AS04-adjuvanted virus-like-particle vaccine - a pilot studyFusion of CTLA-4 with HPV16 E7 and E6 enhanced the potency of therapeutic HPV DNA vaccine.Revealing the density of encoded functions in a viral RNAEfficacy of human papillomavirus 16 and 18 (HPV-16/18) AS04-adjuvanted vaccine against cervical infection and precancer in young women: final event-driven analysis of the randomized, double-blind PATRICIA trial.Immunogenicity of infectious pathogens and vaccine antigens.Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix® or Gardasil® VaccineNaturally Occurring Capsid Protein Variants of Human Papillomavirus Genotype 31 Represent a Single L1 Serotype.Naturally Occurring Major and Minor Capsid Protein Variants of Human Papillomavirus 45 (HPV45): Differential Recognition by Cross-Neutralizing Antibodies Generated by HPV Vaccines.Broad Cross-Protection Is Induced in Preclinical Models by a Human Papillomavirus Vaccine Composed of L1/L2 Chimeric Virus-Like Particles.Impact of 2-, 4- and 9-valent HPV vaccines on morbidity and mortality from cervical cancerSafety of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine in adolescents aged 12-15 years: Interim analysis of a large community-randomized controlled trial.HPV prevalence and genotypes in different histological subtypes of cervical adenocarcinoma, a worldwide analysis of 760 cases.Extending the Human Papillomavirus Vaccination Programme to Include Males in High-Income Countries: A Systematic Review of the Cost-Effectiveness Studies.Different Challenges in Eliminating HPV16 Compared to Other Types: A Modeling Study.Ten-year follow-up of human papillomavirus vaccine efficacy against the most stringent cervical neoplasia end-point-registry-based follow-up of three cohorts from randomized trials.An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression.Worldwide burden of cancer attributable to HPV by site, country and HPV type.Therapeutic potential of an AcHERV-HPV L1 DNA vaccine.The whole story: a systematic review of economic evaluations of HPV vaccination including non-cervical HPV-associated diseases.Human Immunodeficiency Virus/AIDS, Human Papillomavirus, and Anal Cancer.Human Papillomavirus Vaccination of Boys and Extended Catch-up Vaccination: Effects on the Resilience of Programs.Trends in the Incidence of Oropharyngeal Cancers in the United States.Cervical cancer in Africa, Latin America and the Caribbean and Asia: Regional inequalities and changing trends.Human papillomavirus related oropharyngeal cancer.HPV/E7 induces chemotherapy-mediated tumor suppression by ceramide-dependent mitophagy.Carcinogenic HPV prevalence and age-specific type distribution in 40,382 women with normal cervical cytology, ASCUS/LSIL, HSIL, or cervical cancer: what is the potential for prevention?Cancer Registry follow-up for 17 million person-years of a nationwide maternity cohort.Reply to Ryser et al.Carcinogenic human papillomavirus infection.Impact of gender-neutral or girls-only vaccination against human papillomavirus-Results of a community-randomized clinical trial (I).Vaccination protects against invasive HPV-associated cancers.Impacts of human papillomavirus vaccination for different populations: A modelling study.Prevention of HPV disease burden.Evaluation of Dried Blood Spots and Oral Fluids as Alternatives to Serum for Human Papillomavirus Antibody Surveillance.
P2860
Q26769069-051DBB47-6C00-44A3-84E7-08302082E50BQ26770541-80D64C50-399B-4995-BC94-7DE89617A1D9Q26782499-DA54A39D-AEC3-4637-93E7-A26955A9A8B1Q30239987-55FDC90A-4E37-4249-8936-87544650D6A8Q30794549-F71D830B-B08E-4C55-AE4B-DBD1B6BE24C6Q33891821-AE0CDD31-E169-4598-8196-5463617FE33CQ33929216-3E83771F-2EC1-4A86-9F80-847DD02AB869Q34275134-4EDE8B41-51C0-4FD0-BDC5-0E5F5F4F6562Q35129114-D94ADE85-674B-4389-978C-6820D9DCA36AQ35221177-1B61FD8D-6499-4DFF-80C9-5C816476B81CQ35658358-00E87BA9-0537-42E8-B047-8550B20AC409Q35818648-08C76703-08DA-4F67-8FE4-9849B2F03B19Q35861286-E74BFB19-956C-440B-B789-4378E53DA775Q36736614-3274E232-1B97-4403-8A7B-B597E55B3627Q37073299-FC345E15-F785-4B75-8137-086721180A40Q37135163-7E1BD69F-A73B-4378-978C-ABFA6A0602D4Q37561432-B4FEF112-1A32-4EC1-A405-0EC5820E7041Q38206887-2AB29103-AA4D-413D-9034-180C034AC767Q38549643-F496A986-6406-4B8C-9DD3-6EA819C33877Q38599579-2D2BC2B8-4213-496F-9536-A9FE9B761628Q38618078-AC71F2AD-2CAC-4E98-AB61-7C01EDCB090CQ38838178-A8A59976-09E5-494B-9B36-26A0555882DBQ38859779-BA24428E-BEE2-4D10-8045-0DDE6FF8CF75Q38869506-1BD2D4F5-662A-46DC-8147-5B472B0CCDB0Q38997255-4C1AC763-E916-46F8-A19D-DEEFF9B3DC18Q39020800-B15B3764-A153-4A7A-A7FC-E3D6DFA9F316Q39278938-5D149C69-99F8-4A5C-A4C8-B37660EAD5EEQ39955058-E8ECECB9-4D96-4A83-B782-4A09374F904CQ40112605-B7297695-30DA-4695-922F-C7FF073CCA2CQ40152615-B28BBB8F-3F62-4D6D-93DD-EF4B0B4848C1Q40175248-D69F2DE7-CF99-4DBA-A30E-CA26CD42DBF1Q42255129-5018D76F-72D0-42CB-9D69-40F521933839Q42517431-CBD66FAE-00CA-4248-8823-79B1EF15B38CQ44701708-82291E2C-E584-4DA4-9214-2CE91CCA8B3EQ44863515-C7BFCDAF-6E3B-4AD4-B667-C9923361496DQ47603242-FD132052-A718-490D-A613-BAD6962BA847Q48345981-727E1279-B654-42FB-BC70-5C861E689682Q51731914-42DF49DB-0E07-423F-8B19-C6634D9AA461Q51811189-29654FD4-486A-4B0B-B12C-0331D50ABCDBQ54216892-EA1AC1E9-C284-4D18-983E-B898A1EF75CA
P2860
Clinical trials of human papillomavirus vaccines and beyond.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Clinical trials of human papillomavirus vaccines and beyond.
@en
type
label
Clinical trials of human papillomavirus vaccines and beyond.
@en
prefLabel
Clinical trials of human papillomavirus vaccines and beyond.
@en
P2860
P1476
Clinical trials of human papillomavirus vaccines and beyond.
@en
P2093
Matti Lehtinen
P2860
P304
P356
10.1038/NRCLINONC.2013.84
P407
P577
2013-06-04T00:00:00Z